Alkermes to Acquire Avadel, Adding LUMRYZ to Its Portfolio
The $2.1 billion all-cash deal will bring Avadel’s once-nightly oxybate, LUMRYZ, under Alkermes’ umbrella as it advances its orexin agonist pipeline for narcolepsy and other hypersomnolence disorders.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
